Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- 03 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 23 Oct 2017 Status changed from not yet recruiting to recruiting.